Can Chance Pharma’s asthma inhaler challenge Symbicort’s grip on China’s respiratory market?
Asthma drugs are familiar. Delivery remains the problem. CXG87 could test whether better inhaler engineering changes China’s asthma market.
What Glenmark Pharmaceuticals’ Ryaltris commercialization shift means for allergy drug competition
Glenmark Pharmaceuticals is taking direct control of Ryaltris in the U.S. Read what this shift means for allergy drug strategy and specialty growth.
Cipla’s nintedanib approval opens a high-stakes test in the U.S. idiopathic pulmonary fibrosis market
Cipla’s nintedanib approval opens a new chapter in U.S. idiopathic pulmonary fibrosis care. Read what it changes for pricing, access, and competition.
How Glenmark Pharmaceuticals’ fluticasone inhaler approval could reshape the U.S. asthma inhaler market
Glenmark Pharmaceuticals wins FDA approval for generic fluticasone inhaler with 180-day exclusivity. Read what it means for the U.S. asthma drug market.